There are upsides and downsides to this arrangement.
The upside for IVX shareholders, is less dilution. RMW Cho Group is funding the cancer research. So obviously they would want the biggest piece of the pie. I am sure IMU holders on this forum will remember the number of times they had to raise capital to fund research.
Of course, the downside is - for cancer treatments at least, is our arrangement limit us to Australia and NZ.
However, we should remember, this Technology is NOT limited to cancer treatments.
There are still "atherosclerosis and infectious diseases" which we hold the Asia Pacific licence (excluding greater China).
Ann: Complete Regression of TNBC Tumours and Protective Immunity, page-122
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.43M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 13.5¢ | 12.5¢ | $3.286K | 26.26K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 24920 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 9938 | 1 |
View Market Depth
| Last trade - 15.31pm 17/06/2025 (20 minute delay) ? |
| IVX (ASX) Chart |